title: AAV2-mediated subretinal gene transfer of hIFN-α attenuates experimental autoimmune uveoretinitis in mice.
abstract: BACKGROUND
  Recent reports show that gene therapy may provide a long-term, safe and effective intervention for human diseases. In this study, we investigated the effectiveness of adeno-associated virus 2 (AAV2) based human interferon-alpha (hIFN-α) gene therapy in experimental autoimmune uveoretinitis (EAU), a classic model for human uveitis.
  
  
  RESULTS
  An AAV2 vector harboring the hIFN-α gene (AAV2.hIFN-α) was subretinally injected into B10RIII mice at two doses (1.5×10(6) vg, 1.5×10(8) vg). AAV2 vector encoding green fluorescent protein (AAV2.GFP) was used as a control (5×10(8) vg). The expression of hIFN-α in homogenized eyes and serum was detected by ELISA three weeks after injection. The biodistribution of vector DNA in the injected eyes, contralateral eyes and distant organs was determined by PCR. EAU was induced by immunization with IRBP(161-180) three weeks following vector injections, and evaluated clinically and pathologically. IRBP-specific proliferation and IL-17 expression of lymphocytes from the spleen and lymph nodes were assayed to test the influence of the subretinal delivery of AAV2.hIFN-α on the systemic immune response. hIFN-α was effectively expressed in the eyes from three weeks to three months following subretinal injection of AAV2.hIFN-α vector. DNA of AAV2.GFP was observed only in the injected eyes, but not in the distant organs or contralateral eyes. Subretinal injection of both doses significantly attenuated EAU activity clinically and histologically. For the lower dose, there was no difference concerning lymphocyte proliferation and IL-17 production among the AAV2.hIFN-α, AAV2.GFP and PBS injected mice. However, the higher dose of AAV2.hIFN-α significantly suppressed lymphocyte proliferation and IL-17 production.
  
  
  CONCLUSIONS
  Subretinal delivery of AAV2.hIFN-α lead to an effective expression within the eye for at least three months and significantly attenuated EAU activity. AAV2.hIFN-α was shown to inhibit the systemic IRBP-specific immune response.
authors: Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, People's Republic of China.
authors: Lichun
authors: L
authors: Tian
authors: Peizeng
authors: P
authors: Yang
authors: Bo
authors: B
authors: Lei
authors: Ju
authors: J
authors: Shao
authors: Chaokui
authors: C
authors: Wang
authors: Qin
authors: Q
authors: Xiang
authors: Lin
authors: L
authors: Wei
authors: Zhougui
authors: Z
authors: Peng
authors: Aize
authors: A
authors: Kijlstra
references: Gene Ther. 2002 Jun;9(12):804-13
references: 12040462
references: Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15112-7
references: 18809924
references: Ophthalmology. 2004 Mar;111(3):491-500; discussion 500
references: 15019324
references: J Neurosci. 2003 Apr 15;23(8):3302-7
references: 12716937
references: Clin Chim Acta. 2010 Sep 6;411(17-18):1165-71
references: 20416287
references: Annu Rev Immunol. 2005;23:307-36
references: 15771573
references: Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3609-14
references: 11891291
references: Curr Protoc Immunol. 2003 May;Chapter 15:Unit 15.6
references: 18432901
references: Hum Gene Ther. 2006 Aug;17(8):845-58
references: 16942444
references: Gene Ther. 2004 Oct;11 Suppl 1:S26-32
references: 15454954
references: Clin Ophthalmol. 2009;3:559-66
references: 19898628
references: Gene Ther. 2011 Jan;18(1):53-61
references: 20703309
references: Trends Mol Med. 2009 Jan;15(1):23-31
references: 19097940
references: Mol Ther. 2005 Aug;12(2):369-73
references: 16043105
references: J Gene Med. 2009 Jun;11(6):486-97
references: 19340848
references: Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6916-21
references: 9192666
references: Hum Gene Ther. 2005 Sep;16(9):1037-46
references: 16149902
references: Hum Gene Ther. 2008 Oct;19(10):979-90
references: 18774912
references: Curr Opin Ophthalmol. 2007 Nov;18(6):481-6
references: 18163000
references: Ophthalmology. 2010 Jul;117(7):1430-5
references: 20417563
references: Br J Hosp Med (Lond). 2008 Oct;69(10):575-9
references: 18949947
references: Expert Rev Clin Immunol. 2007 Sep;3(5):781-96
references: 20477028
references: Clin Cancer Res. 2008 Dec 15;14(24):8314-20
references: 19088050
references: Mol Ther. 2006 Jun;13(6):1074-84
references: 16644289
references: Mol Vis. 2009 Jul 17;15:1374-82
references: 19626133
references: Mol Vis. 2008 Sep 24;14:1760-9
references: 18836574
references: Mol Ther. 2005 Feb;11(2):275-83
references: 15668139
references: Mol Ther. 2004 Jul;10(1):106-16
references: 15233947
references: Adv Ophthalmol. 1980;40:1-99
references: 6153861
references: N Engl J Med. 2008 May 22;358(21):2240-8
references: 18441370
references: N Engl J Med. 2008 May 22;358(21):2231-9
references: 18441371
references: Immunobiology. 2008;213(9-10):779-87
references: 18926293
references: Gene Ther. 2008 Jun;15(11):849-57
references: 18418417
references: Invest Ophthalmol Vis Sci. 1994 Apr;35(5):2626-31
references: 7909311